DexCom board authorizes $500M share repurchase program through Oct 2024

DEXCOM INC

Board authorized up to $500M repurchase of outstanding common stock.
Repurchase period ends no later than October 31, 2024.
Repurchases may be made on open market or in private transactions at company discretion.
Program does not obligate any repurchases; may be suspended or discontinued at any time.
Timing depends on market conditions and applicable regulatory limits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.